Clinical trials: Gliosarcoma
Brain and Central Nervous System Tumors, Prostate Cancer
Everolimus and Gefitinib in Treating Patients With Progressive Glioblastoma Multiforme or Progressive Metastatic Prostate Cancer
RATIONALE: Everolimus may stop the growth of tumor cells by stopping blood flow to the tumor. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
- Trial name
- NCT00085566
- Testing
- everolimus, gefitinib
- Where
- 2 sites in United States, Spain
- Volunteers
- 61 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma
This phase I/II trial is studying the side effects and the best dose of RO4929097 to see how well it works when given together with bevacizumab compared to bevacizumab alone in treating patients with progressive or recurrent…
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT01189240
- Testing
- gamma-secretase/Notch signalling pathway inhibitor RO4929097, bevacizumab, laboratory biomarker analysis
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme, Gliosarcoma
AMG 102 and Avastin for Recurrent Malignant Glioma
The primary purpose of the study is to assess the response rate of AMG 102 and Avastin treatment in subjects with advanced malignant glioma.
- Trial name
- NCT01113398
- Testing
- AMG 102, Avastin
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Katy Peters
Brain and Central Nervous System Tumors
Erlotinib and Radiation Therapy in Treating Young Patients With Newly Diagnosed Glioma
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00124657
- Testing
- Erlotinib hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 62 people
- Sponsor
- St. Jude Children's Research Hospital
Glioblastoma, Gliosarcoma
Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors
Background: In order to survive, brain tumors must have a network of blood vessels to supply it with oxygen and nutrients. The tumors produce substances that enable new blood vessels to form.
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT00667394
- Testing
- Bevacizumab, MLN-518 (Tandutinib), Quality-of-life assessment
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- National Cancer Institute (NCI)
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide
This phase II trial is studying how well VEGF Trap works in treating patients with recurrent malignant or anaplastic gliomas that did not respond to temozolomide.
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00369590
- Testing
- ziv-aflibercept, pharmacological study, laboratory biomarker analysis
- Where
- 7 sites in United States
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, Gliosarcoma
A Study of PD 0332991 in Patients With Recurrent Rb Positive Glioblastoma
This study will determine the efficacy of the small molecule CDK4/6 inhibitor PD 0332991 (as measured by progression free survival at 6 months) in patients with recurrent glioblastoma multiforme or gliosarcoma who are Rb…
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma
- Trial name
- PD0332991 (NCT01227434)
- Testing
- PD 0332991 (pre-surgery), PD 0332991, Resection as clinical care
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of California, San Francisco
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma
Erlotinib and temsirolimus and may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This phase I/II trial is studying the side effects and best dose of temsirolimus when given together with…
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Diffuse Astrocytoma, Adult Giant Cell Glioblastoma
- Trial name
- NCT00112736
- Testing
- erlotinib, temsirolimus, therapeutic conventional surgery
- Where
- 8 sites in United States
- Volunteers
- 69 people
- Sponsor
- National Cancer Institute (NCI)
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
- Trial name
- NCT00004146
- Testing
- radiation therapy, carboxyamidotriazole, pharmacological study
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. It is not yet known whether the effectiveness of celecoxib in treating glioblastoma multiforme is decreased in patients…
- Trial name
- NCT00068770
- Testing
- radiation therapy, Celecoxib
- Where
- 7 sites in United States
- Volunteers
- 35 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma, Gliosarcoma
Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma
This is a phase II study of Bevacizumab plus Temodar and Tarceva in patients with non-progressive glioblastoma or gliosarcoma. Patients must have stable disease immediately following a standard course of up-front radiotherapy and…
- Trial name
- AVF4120s (NCT00525525)
- Testing
- Bevacizumab, Tarceva, Temozolomide
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- University of California, San Francisco
Glioblastoma, Gliosarcoma
BIBF 1120 for Recurrent High-Grade Gliomas
BIBF 1120 is a newly discovered compound that may stop cancer cells from growing abnormally. This drug is currently being used in treatment for other cancers in research studies and information from those other research studies…
- Conditions
- Glioblastoma, Gliosarcoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT01380782
- Testing
- BIBF 1120
- Where
- 4 sites in United States
- Volunteers
- 37 people
- Sponsor
- Patrick Y. Wen, MD
Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood Anaplastic Oligodendroglioma
Gefitinib and Radiation Therapy in Treating Children With Newly Diagnosed Gliomas
Biological therapies such as gefitinib may interfere with the growth of the tumor cells and may make the tumor cells more sensitive to radiation therapy.
- Conditions
- Untreated Childhood Anaplastic Astrocytoma, Untreated Childhood Anaplastic Oligodendroglioma, Untreated Childhood Brain Stem Glioma, Untreated Childhood Giant Cell Glioblastoma
- Trial name
- NCT00042991
- Testing
- gefitinib, radiation therapy, pharmacological study
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
This phase I/II trial studies lapatinib to see how well it works in treating young patients with recurrent or refractory central nervous system (CNS) tumors.
- Conditions
- Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Giant Cell Glioblastoma
- Trial name
- NCT00095940
- Testing
- lapatinib ditosylate, therapeutic conventional surgery, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
This phase II trial is studying how well vorinostat works in treating patients with progressive or recurrent glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT00238303
- Testing
- vorinostat, conventional surgery
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- National Cancer Institute (NCI)
Adult Giant Cell Glioblastoma, Adult Glioblastoma
Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme
This phase II trial is studying how well giving vorinostat together with bortezomib works in treating patients with progressive, recurrent glioblastoma multiforme.
- Conditions
- Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, Recurrent Adult Brain Tumor
- Trial name
- NCT00641706
- Testing
- vorinostat, therapeutic conventional surgery, bortezomib
- Where
- 214 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma, Gliosarcoma
Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas
Primary objective: To use overall survival to assess the efficacy of the combination of radiation therapy, temozolomide and Avastin followed by Avastin, temozolomide, and irinotecan in the treatment of grade IV malignant glioma…
- Conditions
- Glioblastoma, Gliosarcoma, Brain Tumor
- Trial name
- NCT00597402
- Testing
- Avastin, Temozolomide, Radiation Therapy (XRT)
- Where
- United States
- Volunteers
- 125 people
- Sponsor
- Duke University
Glioblastoma Multiforme, Gliosarcoma
Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme
The primary objective of the study is to determine the efficacy of Avastin in combination with temozolomide and irinotecan in terms of response rate.
- Trial name
- NCT00979017
- Testing
- Avastin, Temozolomide, Irinotecan
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Katy Peters
Glioblastoma, Gliosarcoma
Dose-Intense Temozolomide in Recurrent Glioblastoma
Temozolomide (Temodar) is an FDA approved medication for the treatment of newly diagnosed glioblastomas. In this study, we will be using temozolomide to treat recurrent glioblastomas.
- Trial name
- NCT00657267
- Testing
- Temozolomide
- Where
- 6 sites in United States
- Volunteers
- 58 people
- Sponsor
- Patrick Y. Wen, MD
Glioblastoma, Gliosarcoma
Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma
Primary Objective To estimate 6-month progression free survival probability of patients with recurrent glioblastoma multiforme treated with bortezomib plus Avastin.
- Trial name
- NCT00611325
- Testing
- Avastin, Bortezomib
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Duke University